Faster Diagnostics for Critical Infections
At ESCMID 2026, Inbiome presented new clinical data focused on how molecular diagnostics can accelerate bacterial identification in time-sensitive infections.
Across multiple posters and presentations, the company showcased applications of its Molecular Culture technology in sepsis diagnostics, endocarditis, and implant-associated infections.
The platform identifies bacterial DNA directly from clinical samples, reducing the diagnostic delay associated with conventional culture workflows that often require several days before actionable results become available.
More Than 300 Bacterial Species in a Single Run
According to the data presented during the conference, Molecular Culture can detect more than 300 bacterial species in a single run while fitting into existing laboratory workflows and infrastructure.
The assay also demonstrated detection sensitivity as low as 1-5 CFU, supporting earlier exclusion of bacterial infection and faster clinical decision-making in situations where delays may affect treatment.
Focus on Sepsis Diagnostics
A major focus during ESCMID was the RADOS study in ICU patients with suspected sepsis.
The study compares molecular detection directly with blood culture and examines concordant and discordant findings in real-world clinical practice.
The upcoming webinar featuring Anna Wijen from Maastricht UMC+ and Dries Budding from Inbiome will further discuss:
- RADOS study design in ICU patients
- Molecular versus blood culture comparison
- Concordance and discordant cases
- Handling contaminants and unclear signals
- Clinical interpretation in practice
Moving Beyond Traditional Culture Workflows
As hospitals continue evaluating molecular diagnostics in microbiology, the focus is increasingly shifting toward workflow integration, faster turnaround times, and the clinical value of same-day bacterial identification.